Home' Australian Pharmacist : Australian Pharmacist August 2016 Contents Australian Pharmacist August 2016 I © Pharmaceutical Society of Australia Ltd.
Read in greater detail more regularly than any other pharmacy title –
such constant behaviour means you can count on our readers to open
any issue and be seen!
» Greatest number of recipients opening and reading (82%)
» Greatest number of readers reading every issue (48%)
Engage with almost 18,800 PSA members every month
(15,500 pharmacists in print and 16,000 in digital form).
» Australian Pharmacist is read by 65% of community pharmacists
It has an extremely strong CPD program followed by more than
10,000 pharmacists – a typical monthly article receives 3000 plus
assessments, with highs over 4000!
» Greatest average proportion read (73%)
» Circulation 14,872 cab March 2013
TO ADVERTISE in the best-read pages in pharmacy media and give your campaign real
impact, and greater recognition, contact Tremain Media.
Ph: 02 9988 4689
Ph: 02 9871 5520
Ph: 0402 055 022
*Competitive Advantage Research August 2012 – 632 practicing community pharmacists
Nutura infant formula
Functional Foods Global
The Nutura infant formula brand was
released on to the Australian marketing
in July. As a part of the launch Functional
Foods Global (FFG) announced a
partnership with the National Breast
Cancer Foundation, and analytical
results that it claims ranks Nutura as
superior to other leading brands in
key nutritional areas. FFG says Nutura
formulas have been tested and have
been shown to have some of the highest
levels of calcium, iron, antioxidant
vitamins, phosphorous and L-Carnitine.
It was also found to be high in Omega 3
& 6, DHA, & B group vitamins.
Nutura is available through an online
subscription and home delivery
service and at selected retail outlets
and pharmacies around Australia,
and includes Stage 1 (0-6 months),
Stage 2 (6-12 months) and Stage 3 (1-2
years). It is 100% Australian owned
and uses 100% Australian dairy and is
manufactured in a dedicated facility in
Melbourne. It is the first Infant formula
to be listed as a therapeutic medicine
with the TGA, A step FFG believes
represents a major milestone in product
development and manufacturing
standards for infant nutrition. This
export-only product conforms to
the United Nations international
pharmaceutical inspection cooperation
(PIC) representing a standard in
FFG’s Managing Director, Yossi Spigler
said: ‘All ingredients that enter our
facility are sent away for independent
testing prior to use. Once we have the
finished product, we also send that
away for a full range of independent
testing before it’s released, even though
Australian standards do not require
us to. These are the types of rigorous
standards we believe Australian parents
want and expect.’
Eloctate [efmoroctocog alfa] is now
indicated in patients under 12 years
of age with haemophilia A (congenital
factor VIII deficiency) for the control
and prevention of bleeding episodes,
routine prophylaxis to prevent or reduce
the frequency of bleeding episodes
and perioperative management. The
new indication effectively removes
any age restriction for Eloctate.
Approximately 2,700 people in Australia
have haemophilia of which 2,200 have
haemophilia A and 500 have haemophilia
B. It is estimated that 350 people under
the age of 12 years have haemophilia A.
Eloctate was the first ‘long-acting’ factor
product registered on the ARTG for use
in Australia for haemophilia A, allowing
patients to infuse less frequently
compared to currently available
treatments, reducing treatment burden
and potentially improving adherence.
The product has demonstrated
the ability to provide efficacious
prophylactic protection with infusions
every three to five days or once weekly.
The most commonly identified adverse
drug reactions for Eloctate, with an
incidence of ≥ 0.5 per cent, were
arthralgia, malaise, myalgia, headache
and rash. The TGA approval is based on
the Kids A-LONG study in previously
treated children (under the age of 12
years) with severe haemophilia A. In
the study Eloctate was well tolerated
and efficacious in the prevention and
treatment of bleeding events.
study’s conclusion 90% of participants
were infusing twice weekly.
1. Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor
VIII Fc fusion protein for the prevention and treatment of
bleeding in children with severe hemophilia A. J Thromb
Haemost. 2015;13(6):967–77 .
Items in the Product news section are prepared from information provided by the companies named in each
item. They are included for the information of PSA members. It is up to the individual member to use their
professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses
nor confirms claims made in the items. (Where provided by the company references citing evidence are
included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all
pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy profession or
the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is
the responsibility of the advertisers to comply with the relevant Commonwealth and State law. Advertising does
not constitute an endorsement by PSA of the claims, products or services.
Links Archive Australian Pharmacist July 2016 Australian Pharmacist September 2016 Navigation Previous Page Next Page